Bayer
Commented by Matthias Schomber on November 5th, 2026 | 05:35 CET
Power Shift in the US! Why Bayer Is Booming, TeamViewer Is Plunging and Almonty Industries Could Be on the Verge of a Major Rally!
Power shift in Washington! The Democrats have recaptured the Senate in the US midterm elections and probably the House of Representatives too. For Donald Trump, this means sharing power for the rest of his term, as legislation, taxes and indirectly tariffs will no longer pass quite so easily without the Democrats. The question for the stock market now is whether investors see the setback for the Trump agenda as a threat or a relief. Sectors that depend on regulation, government spending and trade policy in particular could now see greater volatility. Developments in international financial markets are coming thick and fast these days! While Bayer is sending a strong signal with surprisingly strong quarterly results and raised full-year targets, software provider TeamViewer is causing alarm in the SDAX with a sharp slump and a lowered outlook. Meanwhile, an exciting story looks set to unfold in the tungsten sector with Almonty. Following a rapid rise, the shares are undergoing a strong and intense consolidation, which savvy investors could nevertheless see as a rare and attractive buying opportunity. Find out below which stocks have genuine recovery potential following the latest news, where the potential risks lie in detail and how best to position your portfolio for the coming weeks and months. A look behind the scenes suggests markets may be undergoing a complete reassessment right now.
Read
Commented by Armin Schulz on October 27th, 2026 | 05:21 CET
Pharma Stocks with a Future: Bayer, BioNxt Solutions and Novo Nordisk Expand Their Pipelines
No pharmaceutical company can rely on its bestsellers forever. Eventually, patent protection expires, generic manufacturers enter the market, and margins come under pressure. Companies that fail to replenish their product pipelines risk being left behind. That is why substantial sums are currently flowing into new active ingredients, manufacturing facilities and innovative drug delivery methods. Bayer plans to invest USD 2.2 billion in a pharmaceutical plant in Ohio. Smaller developers such as BioNxt Solutions are exploring new formulations and delivery methods for established active ingredients. At the end of September, Novo Nordisk agreed to license an oral drug candidate, including an upfront payment of USD 300 million. We take a closer look at Bayer, BioNxt Solutions and Novo Nordisk.
Read